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1. Introduction 
The molecular mechanisms of neurodegeneration in Parkinson’s disease and the cause of 
the selective dopaminergic neuronal loss are mostly unknown. Many pathogenetic factors 
have been found to play a role but the relationships among these factors, together with the 
reasons of the high vulnerability of dopaminergic neurons to them, have not been 
completely defined. Only a small fraction of Parkinson’s disease cases have a defined 
etiology: this fraction include the monogenic hereditary variants of the disease and the 
sporadic cases determined by prolonged exposition to toxic agents inhibiting mitochondrial 
complex I, such as 1,1’-dimethyl-4,4’-5 bipyridinium (paraquat), rotenone and 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP). Parkinson’s disease-related toxins and 
pathogenetic mutations have been indispensable to create cell and animal models with the 
aim to clarify the molecular physiopathology of the disease. Little is known about the 
primitive causes of idiopathic Parkinson’s disease, that probably represents a multi-factorial 
disease influenced by various genetic and environmental factors, all characterized by high 
incidence in general population. The different risk factors together would contribute to 
initiate the complex pathogenetic sequence of events leading to the death of dopaminergic 
neurons.  
Recently, Parkinson’s disease has been placed in the large category of neurodegenerative 
diseases caused by protein misfolding. In particular, alpha-synuclein has been proposed as 
the central and most specific factor implied in the pathogenesis of this syndrome, which, as 
a consequence, has been classified among synucleinopathies, together with dementia with 
Lewy bodies and multiple system atrophy, other neurodegenerative diseases having alpha-
synuclein pathology as a major feature. 
Aim of this chapter is to provide an organic revision of evidences for the involvement of 
alpha-synuclein in the pathogenesis of Parkinson’s disease. We will define the mechanisms 
responsible for the toxic gain of function of ǂ-synuclein and the processes triggered by 
aberrant alpha-synuclein and mediating its neurotoxic effect. Particular attention will be 
paid to establish the links that correlate the deleterious action of alpha-synuclein with 
oxidative stress and with the efficiency of the processes involved in the clearance of aberrant 
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proteins; these last include the ubiquitin-proteasome system  and the autophagic-lysosomal 
pathways. Both oxidative stress and impairment of protein degradation machinery exert a 
neurotoxic effect contributing to the pathogenesis of Parkinson’s disease and partially 
mediated, in dopaminergic neurons, by qualitative and quantitative alterations in alpha-
synuclein. This protein in turn  is able to boost the processes responsible for its toxic gain of 
function. Therefore, a physiopathologic circuit emerges constituted by a complex interaction 
among different pathogenetic mechanisms, everyone able to support the others; the death of 
dopaminergic neurons represents the ultimate and irreversible outcome of all these events. 
This chapter aims at clarifying this complex dynamics responsible for the neurodegenerative 
process, with particular regard to mechanisms both determining and mediating the 
deleterious effect of alpha-synuclein. Furthermore, we will report data on the development 
of biochemical tests helpful for diagnosis and prognosis and useful as objective criteria to 
determine the neuroprotective effectiveness of drugs in clinical trials: in this regard, levels 
and modifications of ǂ-synuclein, as well as parameters of oxidative stress and autophagy, 
could represent suitable peripheral biomarkers of disease risk and progression. Finally, we 
will discuss about the opportunity of interfering with all the reported pathogenetic 
mechanisms as putative neuroprotective pharmacologic strategy. 
2. Alpha-synuclein toxicity 
Alpha-synuclein is a 144aa protein encoded by the gene SNCA, localized at 4q chromosome. 
Three different SNCA transcripts can be detected in neurons. The physiological functions of 
alpha-synuclein is still not fully understood. It is abundantly expressed in nervous tissues 
and it localizes in the cytoplasm or associated with lipid membranes. In particular, this 
protein is mainly localized in the pre-synaptic compartment, where it seems to have a role in 
regulating neurotransmitter release, vesicle turnover,  membrane stability and neuronal 
plasticity. 
The hypothesis of an active involvement of alpha-synuclein in the pathogenesis of 
Parkinson’s disease was proposed when this protein was identified as the main component 
of Lewy bodies, intraneuronal aggregates constituting a constant report in the 
neuropathology of Parkinson’s disease (Spillantini et al 1997). Beside alpha-synuclein, Lewy 
bodies also contain components of proteasome machinery, chaperone proteins, alpha-
tubulin, synphilin-1, glyceraldehyde 3-phosphate dehydrogenase and several other proteins 
known to be involved in nigral neurodegeneration. Residues 71 to 82 of alpha-synuclein are 
essential for the assembly of Lewy bodies. The exact role of these inclusions in the disease 
physiopathology was unknown for several years. 
The key function of alpha-synuclein protein in the pathogenesis of Parkinson’s disease was 
first elucidated by genetic studies: the finding of familial cases of Parkinson’s disease 
genetically linked to missense mutations in the SNCA gene and to genomic triplication of 
the wild type gene gave evidence of the potential neurotoxic effect of this protein. The first 
causal mutation of hereditary Parkinson’s disease was identified in a large Italian family 
(“Contursi kindred”, from the name of the town): it was the missense mutation Ala53Thr in 
the SNCA gene (Polymeropoulos et al 1997). Only two other pathogenetic missense 
mutations have been identified in SNCA: Ala30Pro and Glu46Lys. All these variants are 
located in the N-terminus of the protein and are linked to autosomal dominant forms of 
Parkinson’s disease. Anyway, the missense mutation frequency in SNCA in different 
populations is very low, whereas SNCA multiplications are a bit more frequent. The 
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Ala53Thr alpha-synuclein mutant is responsible for the greater in vivo neurotoxicity in 
transgenic animal models.  
The deleterious effects of these genetic alterations on dopaminergic neurons have been 
demonstrated in cellular and animal models, confirming the hypothesis that both qualitative 
and quantitative alterations of alpha-synuclein are able to trigger its toxic effect: mutant 
alpha-synuclein protein exerts a selective toxicity in dopaminergic neurons when expressed 
in rats; at the same time, the mutant protein causes aggregation and formation of Lewy 
bodies in dopaminergic neurons of mouse models.  
The toxicity of both mutant and wild type alpha-synuclein seems to require the acquisition 
of a misfolded conformation which prevents alpha-synuclein degradation and favors its 
fibrillization, firstly into protofibrillar oligomeric species and then to fibrillar aggregates. 
Recently, it has become clear that insoluble aggregates probably do not have an intrinsic 
toxic function, as suggested by the finding that Lewy bodies–positive dopaminergic neurons 
are less vulnerable to degeneration. Furthermore, the increased size of Lewy bodies and  the 
decreased levels of soluble alpha-synuclein correlate with a higher resistance to cytotoxic 
agents. Therefore, formation of Lewy bodies could represent a protective phenomenon 
favoring the removal of soluble oligomers. Different mechanisms can explain the negative 
effects exerted by alpha-synuclein oligomers, which seem to be directly responsible for the 
neurotoxic effect of the protein (Vekrellis et al 2004):  
• Binding to microtubules and dysregulation of cytoskeleton functions.  
• Damaging of mitochondrial and other cellular membranes.  
• Interaction with other proteins and modulation of their activity.  
Alpha-synuclein oligomers directly interfere with proteasome subunits. Furthermore, alpha-
synuclein impairs microtubule stability through binding to alpha-tubulin  and to the 
microtubule associated protein TAU. Alpha synuclein induces the aggregation of TAU, 
which in turn favors alpha-synuclein fibrillization; interestingly, polymorphisms in the TAU 
gene have proved to modify the risk of developing Parkinson’s disease.  
In monogenic forms of Parkinson’s disease the direct neurotoxic effect of mutant alpha-
synuclein may depend on specific conformational modifications, modulating the propensity 
of the protein to aggregate, to interact with other proteins and to be processed by clearance 
mechanisms. Pathogenetic mutations of alpha-synuclein protein are known to confer a 
tendency to acquire abnormal conformation substantially easier than the wild type protein, 
which accounts for the development of Parkinson’s disease in patients having these 
mutations. 
The fact that over-expressed wild type alpha-synuclein is responsible for neurotoxicity 
suggests that even simple protein accumulation is able to trigger the misfolded 
conformation and to promote protein aggregation.  
As well as in familial cases, even in sporadic Parkinson’s disease the toxic gain of function of 
alpha-synuclein could derive from the intraneuronal accumulation of the protein or from 
biochemical modifications enhancing the propensity of the protein to aggregate. Anyway, 
the ubiquitous expression and the high levels of alpha-synuclein in the brain suggests that 
its simple presence in dopaminergic neurons is not sufficient to explain the selective 
degeneration of these cells, which must have specific characteristics able to induce or to 
accelerate alpha-synuclein misfolding, oligomerization and aggregation. Oxidative stress 
and production of highly reactive aldehydes, both depending on high levels of dopamine, 
can modify alpha-synuclein, partially explaining the high tendency of this protein to acquire 
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a misfolded conformation in dopaminergic neurons. Indeed, dopamine promotes alpha-
synuclein protofibrils formation. Oxidative stress, which is known to be one of the main 
pathogenetic factors leading to the death of dopaminergic neurons in Parkinson’s disease, 
has been identified as a major responsible for alpha-synuclein post-translational 
modifications, consisting in oxidation and nitration of specific aminoacid residues; these 
alterations in alpha-synuclein have been detected in nigral neurons of brain samples from 
patients with Parkinson’s disease (Giasson et al 2000) and from animal models of disease 
(Gao et al 2008).  
An increase in alpha-synuclein levels, correlated with the degree of nigrostriatal dopamine 
depletion, has been demonstrated in the substantia nigra of patients with sporadic 
Parkinson’s disease (Chu et al 2007). It is conceivable to suppose that this accumulation of 
the toxic protein might derive from an increase in transcription and translation of the SNCA 
gene or from a decrease in the protein degradation.  
The variability in codifying and non-codifying SNCA gene sequences has demonstrated to 
modify the risk of developing sporadic Parkinson’s disease, probably through a mild 
modulatory effect on transcription activity and, as a consequence, on intraneuronal levels of 
alpha-synuclein. SNCA duplication was found in sporadic cases of Parkinson’s disease. 
Increasing length in the dinucleotide repeat sequence (REP1) of the SNCA gene promoter  
has been demonstrated to be correlated with an increased risk of developing sporadic 
Parkinson’s disease (Maraganore et al 2006; Brighina et al 2008). Furthermore, single 
nucleotide polymorphisms at the promoter region and at the 3' end of SNCA gene have 
been found to modify the risk of disease.  
Anyway, aging remains the most evident risk factor for sporadic Parkinson’s disease. An 
interesting hypothesis suggests that senescence of dopaminergic neurons could promote 
the accumulation of misfolded alpha-synuclein through two main mechanisms: slowing 
alpha-synuclein turnover through the impairment of clearance machinery; impairing the 
function of mitochondria and antioxidant systems, with consequent increase in oxidative 
stress. 
Great efforts have been done in order to identify genetic and environmental factors able to 
modulate the aging process. Caloric restriction represents the only environmental condition 
which has demonstrated to delay aging in a wide range of organisms. This evidence 
suggests that caloric restriction might guarantee protection from developing Parkinson’s 
disease and could delay the disease progression. As it was supposed, caloric restriction has 
shown a protective effect in MPTP-induced animal models of Parkinson’s disease, even if an 
epidemiologic correlation between diet and incidence of Parkinson’s disease has not been 
demonstrated. The molecular basis of the protective role of caloric restriction in animal 
models has been elucidated in yeast, where a family of NAD+-dependent protein 
deacetylases, called sirtuins (SIRTs), have been identified as mediators of the changes 
induced by starvation in cells; many sirtuins analogs have been discovered in mammals. 
These proteins regulate cell homeostasis partially through an epigenetic mechanism: they 
modulate histones acetylation and chromatin condensation. SIRT1 is a major responsible for 
protective cell modifications during starvation, whereas other SIRTs seem to exert a specific 
deleterious effect on dopaminergic neurons. In particular, SIRT2, an alpha-tubulin 
deacetylase, promotes formation of alpha-tubulin oligomers, which destabilize microtubules 
and form toxic complexes with alpha-synuclein oligomers. The interaction of alpha-
synuclein oligomers with alpha-tubulin plays an important role in mediating alpha-
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synuclein toxicity. The NAD+ concentration-dependency of SIRT2 activity suggests a 
possible modulation of alpha-synuclein misfolding and aggregation by energy metabolism.  
3. Oxidative stress, mitochondrial dysfunction and excitotoxicity  
An impairment in multiple steps of the mitochondrial respiratory chain has been 
demonstrated in Parkinson’s disease (Schapira et al 1998). The importance of this 
pathogenetic mechanism mainly depends on its role of main source of reactive oxygen 
species. At the same time, the loss of mitochondrial function and the consequent energetic 
deficit interfere with glutamate uptake and increase neuronal vulnerability to glutamate 
excitotoxicity.   
3.1 Mitochondrial dysfunction  
Several epidemiologic and experimental data confirm the importance of mitochondrial 
derangement in the pathogenesis of Parkinson’s disease. First of all, electron transport 
complex I represents the main molecular target of paraquat, rotenone and MPTP, the 
exogenous substances known to determine degeneration of human dopaminergic 
neurons. The selective toxicity of MPTP on dopaminergic neurons derives from its 
transformation to the metabolite 1-methyl-4-phenyl-pyridium (MPP+), which is 
concentrated within dopaminergic neurons by dopamine transporters. Even paraquat, 
which is structurally similar to MPP+, is carried into dopaminergic cells by the same 
transporter. In contrast to MPTP and paraquat, rotenone is not concentrated in nigral 
neurons, nevertheless it produces selective death of these cells. The development of 
parkinsonism after exposure to rotenone represents a further proof of the high 
susceptibility of dopaminergic neurons to mitochondrial impairment. Toxic derangement 
in complex I induces alpha-synuclein aggregation and formation of Lewy body-like 
inclusions (Betarbet et al 2000). 
A reduced activity of the mitochondrial complexes I and IV has been observed in the 
substantia nigra of patients with Parkinson’s disease and in animal models of disease 
(Palacino et al 2004). Decreased levels of coenzyme Q10 together with a higher ratio of 
oxidized vs. reduced Coenzyme Q10 have been observed in patients. An increase of cerebral 
lactate levels, suggesting an alteration in aerobic metabolism as a consequence of 
derangement of mitochondrial respiratory chain, has been detected by brain magnetic 
resonance spectroscopy in patients with Parkinson’s disease (Henchcliffe et al 2008). 
Experiments performed on cytoplasmic hybrid cell lines from patients with Parkinson’s 
disease suggest that the complex I deficit associated to the disease might be genetically 
determined by defects in mitochondrial DNA. A single nucleotide polymorphism within the 
gene encoding NADH dehydrogenase 3 of complex I has been associated to a decrease in 
the risk of sporadic Parkinson’s disease, providing genetic evidence of the pathogenetic 
relevance of complex I activity (van der Walt et al 2003). 
An endogenous substance able to impair mitochondrial function is salsolinol, which is 
synthesized from dopamine and acetaldehyde by salsolinol synthase. This molecule has 
been found in various regions of the brain, including striatum and substantia nigra. 
Salsolinol inhibits mitochondrial complex II and this effect may explain the fact that high 
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Alpha-synuclein contains a mitochondrial targeting sequence. Over-expression of this 
protein favors its translocation to the mitochondria. The damage of these organelles seems 
to be one of the mechanisms mediating the toxic effects of alpha-synuclein oligomers.  
An additional confirmation of the importance of mitochondrial function for the homeostasis 
of dopaminergic neurons is the finding that some proteins linked to hereditary forms of 
Parkinson’s disease exert their function within mitochondria; furthermore, pathogenetic 
mutations of the genes encoding for some of these proteins are associated with the 
impairment of mitochondrial function, which might be the main neurotoxic action exerted 
by these mutations: 
• PTEN induced putative kinase 1 (PINK1/PARK6) is a kinase that localizes in the 
mitochondrial membrane. Its loss of function is associated with a decrease in complex I 
activity determining an increase in oxidative stress. Mutations of PINK1 gene are 
responsible for recessive forms of Parkinson’s disease. 
• DJ-1 (PARK7) is a protein found to be mutated in recessive forms of Parkinson’s 
disease. It plays a role in cell protection during oxidative stress, which induces the 
translocation of the protein to the mitochondrial matrix and the intermembrane space. 
The loss of DJ1 has been associated to depolarization and fragmentation of 
mitochondria. 
• Leucine-rich repeat kinase 2 (LRRK2/PARK8) is a kinase linked to dominant forms of 
Parkinson’s disease. It is mainly localized in the cytosol but a fraction can be found in 
the outer mitochondrial membrane. Pathogenetic mutations determine an increase in 
the kinase activity of the protein. 
• High temperature requirement proteinA2 (HTRA2/Omi/PARK13) is a mitochondrial 
protease which has been associated with recessive forms of Parkinson’s disease. Its loss 
of function has revealed to produce mitochondrial damage.  
3.2 Oxidative stress 
Free radicals include reactive oxygen species and reactive nitrogen species. During cell 
metabolism some of these substances are normally produced: superoxide anion, hydrogen 
peroxide, nitric oxide, peroxynitrite, nitroxyl and hydroxy radical. These products can be 
responsible for the damage of protein, DNA and lipid. 
The brain contains a high amount of substances, such as  phospholipids and free fatty 
acids, which are vulnerable to oxidative modifications and, as a consequence, are 
responsible for the high vulnerability of the central nervous system to the deleterious 
action of free radicals. Lipid peroxidation represents a key mechanism mediating the 
toxicity of free radicals on a wide range of cell organelles and functions. Free radicals 
initiate peroxidation of the membrane lipids making them lose a hydrogen atom from a 
methylene group, with formation of a diene; this product mediates the formation of a 
peroxy radical through reaction with oxygen; the peroxy radical abstracts a hydrogen 
atom from another lipid to form hydroperoxides, which mediates the propagation of lipid 
peroxidation.  
In physiologic conditions free radicals are rapidly converted into non toxic molecules by 
antioxidants, which prevent oxidation of other molecules, thus protecting cell from 
oxidative stress. The cell antioxidant system include four main  molecules:  
• Catalase is a heme-protein localized in peroxisomes, which catalyzes the decomposition 
of hydrogen peroxide to water and oxygen. 
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• Superoxide dismutase is a cytosolic, mithocondrial and extracellular metallo-protein 
which catalyzes the transformation of superoxide into O2 and H2O2. 
• Reduced glutathione is a tripeptide which exerts an important reducing activity of 
reactive oxygen species through its conversion to glutathione disulfide.  
• Glutathione peroxidase is an enzyme which catalyzes the reduction of H2O2 to water 
and O2 by reduced glutathione. 
A large amount of studies have demonstrated that oxidative damage plays a major 
pathogenetic role in Parkinson’s disease and represents a key contributor to the loss of 
dopaminergic neurons (Jenner & Olanow 1998). The high concentration of dopamine is 
presumed to be essential to determine the high vulnerability of dopaminergic cells to 
oxidative stress. Dopamine itself does not seem to exert direct toxic effects at physiologic 
concentrations, but toxic intermediates derive from its catabolism:  
• Auto-oxidation of dopamine leads to the production of semiquinones, which have an 
intrinsic toxic effect and generate reactive oxygen species.  
• The enzymatic metabolism of dopamine, mediated by monoamine oxidase B, leads to 
the generation of H202; therefore, the inhibition of monoamine oxidase B by selective 
drugs may protect against production of some toxins and free radicals deriving from 
dopamine oxidation. 
The experimental stimulation of dopamine catabolism by  monoamine oxidase B leads to an 
increase in oxidative stress levels, thus confirming the deleterious role of dopamine 
derivatives on neuronal oxidoreductive equilibrium. 
Extensive studies performed on postmortem brain samples have provided evidence 
supporting the involvement of oxidative stress in the pathogenesis of Parkinson’s disease. 
Elevated levels of reactive oxygen species have been detected by assessment of lipid 
peroxidation, protein oxidation and DNA damage in nigrostriatal regions of patients with 
Parkinson’s disease and in animal models: 
• Malondialdehyde, 4-hydroxy-2,3-nonenal and thiobarbituric acid reactive substances 
(TBARS) are markers of lipid peroxidation which are elevated in the substantia nigra 
and striatum of diseased patients (Yoritaka et al 1996). 
• Markers of oxidative damage to proteins, such as carbonyl modifications of aminoacid 
residues, are increased in substantia nigra of patients with Parkinson’s disease (Alam et 
al 1997). 
• An increase in oxidative alterations of nucleic acids was detected in midbrain of 
diseased patients (Zhang et al 1999). 
On the other hand, a dysregulation of multiple antioxidant systems has been demonstrated 
in Parkinson’s disease:  
• An increase in superoxide dismutase and catalase levels has been detected in striatum 
and midbrain of animal models (Keeney et al 2006). This feature probably represents a 
compensatory reaction of cell control systems, aimed at neutralizing the increasing 
levels of reactive oxygen species.  
• A decrease of reduced glutathione levels was detected in the substantia nigra and 
corpus striatum of patients with Parkinson’s disease and in animal models (Pearce et al 
1997). Glutathione deficiency could be a consequence of the high levels of free radicals, 
which rapidly oxidize glutathione to glutathione disulfide, or, alternatively, it might 
represent an early pathogenetic feature which contributes to the high vulnerability of 
dopaminergic neurons to oxidative stress.  
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The iron-catalyzed conversion of H202 into hydroxyl radicals is supposed to contribute to 
oxidative stress and neurodegeneration in Parkinson’s disease; this remark is based on the 
finding of increased iron content in postmortem brain samples from diseased patients. 
Various proteins linked to recessive hereditary forms of Parkinson’s disease play an 
important role in cell response to oxidative stress. In particular, an increase in protein and 
lipid peroxidation has been demonstrated in parkin defective animal models, suggesting 
that a defect in the ubiquitin-proteasome pathway or in formation of Lewy bodies can favor 
the generation of free radicals.  
The mechanisms mediating the neurotoxic effects of oxidative species in dopaminergic 
neurons are complex and only partially understood, but a central role seems to be played by 
the alterations that free radicals produce on alpha-synuclein conformational status and 
degradation. Indeed, it has been demonstrated that oxidative stress induces intraneuronal 
accumulation and aggregation of alpha-synuclein and formation of Lewy bodies-like 
inclusions. This effect might be  produced through a double mechanism:  
• Reactive oxygen species directly generate post-translational modifications in alpha-
synuclein residues, enhancing the tendency of the protein to aggregate. 
• High levels of free radicals determine a down-regulation of both the ubiquitin-
proteasome system and the autophagy-lysosomal pathway, thus impairing the entire 
degradative machinery of alpha-synuclein.  
The deleterious effect of oxidative stress on the function of clearance systems might partially 
depend on direct alteration of proteins regulating and mediating these pathways; at the 
same time, oxidative stress produces ATP depletion through damage of mitochondrial 
membranes, thus interfering with all energy-dependent processes, such as the clearance of 
proteins and organelles.  
3.3 Excitotoxicity 
Several lines of experimental evidence indicate that a toxic effect exerted by high levels of 
glutamate in the synaptic cleft contributes to the neurodegeneration of dopaminergic 
neurons in Parkinson’s disease. Excitotoxicity is a pathogenetic mechanism that has 
demonstrated a role in the neuronal death in different neurologic diseases, both acute and 
chronic (Ferrarese & Beal 2004).  
The molecular processes that mediate glutamate effects on neuronal survival consist on a 
complex cascade of events that ultimately results in neuronal death. Overactivation of the 
N-methyl-D-aspartate (NMDA) receptors seem to mediate a great part of this neurotoxic 
effect through generation of a calcium overload. Indeed, NMDA receptors are permeable to 
calcium ions, so that their activation results in an increase in the cytoplasmatic concentration 
of this element; high intracellular levels of calcium are responsible for the activation of 
several pro-apoptotic pathways and for induction of oxidative stress through activation of 
oxygenases and perturbation of mitochondrial homeostasis.  
Oxidative and nitrosative stress represent important processes both favoring and mediating 
excitotoxic damage. An increase in the production of free radicals has been demonstrated in 
neurons exposed to excitotoxic insults. Nitric oxide is produced in response to NMDA 
receptors activation thanks to the interaction of nitric oxide synthase with these receptors; 
nitric oxide contributes to the generation of free radicals and is involved in the activation of 
the pro-apoptotic cascade. These data suggest that oxidative stress gives an important 
contribution to the excitotoxic process downstream of glutamate receptor activation. 
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Furthermore,  reactive oxygen species have been identified as agents able to induce the 
increased release of glutamate during pathologic conditions. In fact, lipid peroxidation of 
presynaptic membrane seems to impair the function of transporters involved in the 
maintenance of calcium homeostasis, resulting in sustained elevation of this ion in the 
presynaptic terminal, which is depolarized and so releases glutamate into the synaptic cleft; 
moreover, oxidative stress directly impairs glutamate transporter function in astrocytes and 
neurons, leading to an increase in concentrations of extracellular glutamate, which can bind 
postsynaptic receptors and mediate excitotoxicity.  
Glutamate transport is an energy-dependent process, which explains, together with oxidative 
stress, the fact that mitochondrial dysfunction determine a decrease in the reuptake of 
glutamate and, as a consequence, an increase in neuron vulnerability to excitotoxicity. 
Based on this strong relationship among oxidative stress, mitochondrial dysfunction and 
excitotoxicity, it is easy to imagine an involvement of glutamate toxicity in the pathogenesis 
of Parkinson’s disease, where free radicals and mitochondrial impairment are known to play 
a major role. In animal models of disease modifications in the abundance and 
phosphorylation status of the different NMDA receptor subunits have been detected 
(Dunah et al 2000). Anyway, the importance of excitotoxicity in the degeneration of nigral 
dopaminergic neurons might be increased by the complex set of changes that nigrostriatal 
dopamine depletion triggers in functional anatomy of basal ganglia circuitry. In particular, 
the reduction of the nigrostriatal dopaminergic transmission produces a strong increase in 
the glutammatergic activity of the subthalamic projection, normally inhibited by nigral 
neurons. This hyperactivity critically contributes to the onset of parkinsonian motor 
symptoms, as confirmed by the evidence that electric suppression of subthalamic nucleus 
through deep brain stimulation improves motor functions. Furthermore, these functional 
alterations in basal ganglia circuitry might have pathogenetic implications: overactivation of 
subthalamic glutammatergic transmission to substantia nigra could promote the excitotoxic 
damage of dopaminergic neurons, favoring neuronal death and accelerating disease 
progression; this concept has been confirmed by the beneficial effects obtained by blockade 
of subthalamic activity in animal models of Parkinson’s disease (Blandini et al 2001). 
Therefore, excitotoxicity appears to be an important contributor to neuronal death in the 
substantia nigra of patients with Parkinson’s disease; this mechanism correlates with 
oxidative stress and is amplified by subthalamic overactivation.  
4. Role of clearance mechanisms 
Emerging data support the view that dysregulation of alpha-synuclein clearance machinery 
might represent the key feature leading to the intraneuronal accumulation of this protein. 
These mechanisms include the ubiquitin-proteasome system and the autophagic-lysosomal 
pathways; the autophagic pathways involved in the degradation of alpha-synuclein are 
chaperone-mediated autophagy and macroautophagy (Webb et al 2000). Anyway, the 
accumulation of alpha-synuclein does not represent the only negative consequence of 
clearence systems failure. 
4.1 Impairment of the ubiquitin-proteasomal system 
Increasing evidences indicate that the ubiquitin–proteasome pathway is defective in 
Parkinson’s disease. The finding that Lewy bodies are ubiquitin-positive aggregates has 
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suggested that a dysfunction in proteasome might contribute to the accumulation and 
aggregation of alpha-synuclein and other neurotoxic proteins. The first confirmation of this 
hypothesis has derived from the identification of hereditary forms of Parkinson’s disease 
linked to two genes within the ubiquitin-proteasome system: parkin and UCHL1.  
Parkin (PARK2) is an ubiquitin E3 ligase, an enzyme that catalyzes the addition of ubiquitin 
chains to substrate proteins which must be degraded by the proteasome. Mutations in parkin 
gene are responsible for almost half of autosomal recessive cases of hereditary Parkinson’s 
disease (Kitada et al 1998); most of the pathogenetic mutations are associated with a defect in 
the E3 ubiquitin ligase activity of the protein. Furthermore, parkin is responsible for K63 
ubiquitination of alpha-synuclein; this function is not involved in the degradation of substrate 
proteins through proteasome but favors protein aggregation and generation of insoluble 
inclusions. Mutations in the parkin gene prevent the formation of Lewy bodies in the 
substantia nigra, thus suggesting that the K63 ubiquitin ligase function of parkin is essential 
for the fibrillization of alpha-synuclein and formation of insoluble inclusions; the degeneration 
of dopaminergic neurons deriving from parkin loss of function supports the hypothesis that 
Lewy bodies might contrast the toxic effects of the protofibrillar protein.  
Ubiquitin C-terminal hydrolase L1 (UCHL1/PARK5) is an enzyme that cleaves peptide-
ubiquitin bonds and recycles ubiquitin monomers. Variants of UCHL1 gene have been 
associated to familial forms of Parkinson’s disease. The I93M mutation was identified in a 
family with probable autosomal dominant Parkinson’s disease; in vitro studies have 
demonstrated that this mutation results in partial loss of UCHL1 hydrolytic activity. In 
addition to the hydrolase activity, UCHL1 exerts a dimerization-dependent ubiquitin ligase 
activity that promotes alpha-synuclein aggregation. The single nucleotide polymorphism 
S18Y, which has been found to decrease the susceptibility to sporadic disease, seems to be 
associated with reduced ligase activity. 
A direct proof of proteasome dysfunction in Parkinson’s disease has been the finding of 
structural and functional alterations in the 20S proteasome subunit in the substantia nigra of 
patients with sporadic disease. The pathogenetic relevance of proteasome impairment has 
been reinforced by the observation that administration of proteasomal inhibitors to animals 
can produce the neuropathological and motor manifestations of Parkinson’s disease, 
including selective nigral cell loss, Lewy-bodies-like inclusions and typical clinical signs. 
Two mechanisms are known to be responsible for a dysfunction in the ubiquitin-proteasome 
system: aging is associated with a physiologic decrease of proteasome efficiency and 
ubiquitination activity; oxidative species and alpha-synuclein protofibrils exert a deleterious 
effects on proteasome subunits.  
Alpha-synuclein oligomers have demonstrated to inhibit proteasome function through 
direct interaction with 20S subunit; this effect might favor further accumulation of alpha-
synuclein, which in turn may worsen proteasome impairment.  
The mechanisms behind proteasome inhibition by oligomeric alpha-synuclein require 
further investigation in order to be clarified. Synphilin-1 has been associated to the 
pathogenesis of Parkinson’s disease since its identification as an alpha-synuclein-interacting 
protein, a component of Lewy bodies and a substrate of the E3 ligase parkin. This protein 
has been found to interact with the protein S6 ATPase, which exerts a regulatory function on 
proteasome. Furthermore, recent studies indicate that synphilin-1 exerts an inhibitory effect 
on proteasome activity partially due to the interaction with alpha-synuclein (Alvarez-
Castelao et al 2010); mutations in synphilin-1 gene have been detected in patients with 
sporadic Parkinson’s disease.    
www.intechopen.com
Alpha-Synuclein, Oxidative Stress and  
Autophagy Failure: Dangerous Liaisons in Dopaminergic Neurodegeneration 
 
121 
Chronic oxidative stress alters the subunits of proteasome, so that even reactive oxygen 
species might be responsible for proteasome impairment in Parkinson’s disease. 
4.2 Autophagy dysfunction 
Autophagy is a finely regulated intracellular process that mediates lysosomal degradation of 
proteins and organelles. Its function allows the clearance of substrates characterized by 
alterations limiting their physiologic function or responsible for a cytotoxic effect. This 
degradative process exerts a cytoprotective role that is probably dependent on the clearance 
of toxic intracellular structures and the catabolism of substrates in order to obtain energy 
during starvation. Anyway, in particular situations autophagy seems to mediate a specific 
pathway of programmed cell death; this function requires a strong activation of autophagy 
and until now, in vivo, has been identified only during involutional physiologic processes in 
embryonic tissues (Nixon et al 2006).      
In mammalian cells autophagy encompasses three main processes: microautophagy, 
macroautophagy and chaperone-mediated autophagy. Microautophagy is a constitutive, 
non selective process consisting on endocytosis of small  amounts of cytoplasm into 
lysosomes through invagination of lysosomal membrane. Macroautophagy and chaperone-
mediated autophagy are inducible processes: the first one allows lysosomal degradation of 
organelles and proteins after their sequestration within a double-membrane-limited vacuole 
called autophagosome; the second one is a selective device for degradation of aberrant 
proteins, which are directly transported into the lysosomal lumen by a translocation system 
constituted by specific carrier proteins. 
Recent research has revealed the existence of a dysfunction in autophagy pathways in the 
cerebral regions involved in neurodegenerative processes. A decrease in the activity of both 
autophagic-lysosomal pathway and the ubiquitin-proteasome system has been reported 
during aging in every tissue, included neurons (Martinez-Vicente et al 2005). This deficit 
might be a major responsible for the intracellular accumulation of misfolding proteins and 
aberrant mitochondria, representing factors leading to oxidative stress and neuronal 
damage. Therefore, autophagy impairment might be a primum movens of the 
neurodegenerative processes and, at the same time, a limiting factor that is necessary for 
preventing early onset of massive neuronal loss. 
In the last years the pathogenetic role of altered clearance machinery has become a central 
subject of research in Parkinson’s disease: indeed, the impairment of chaperone-mediated 
autophagy and macroautophagy, together with the dysfunction of ubiquitin-proteasome 
system, seems to give a major contribute to the development and progression of nigral 
degeneration. The loss of function of these degradative pathways might produce a 
deleterious effect through induction of the pathogenetic processes more directly responsible 
for neuronal death, such as the accumulation and oligomerization of alpha-synuclein, the 
persistence of damaged mitochondria and the consequent production of reactive oxygen 
species. In turn, these key mediators of dopaminergic neurodegeneration can further worsen 
the impairment of clearance machinery and, in particular, of autophagic pathways (Cuervo 
et al 2010). 
4.2.1 Impairment of chaperone-mediated autophagy 
Chaperone mediated autophagy mediates the translocation of proteins containing a Lys-
Phe-Glu-Arg-Gln (KFERQ) motif into lysosomes. This process requires the presence of three 
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main proteins: cytosolic heat shock protein 70 (hsc70), lysosomal hsc70, lysosomal-
associated membrane protein 2A (lamp2A). Cytosolic hsc70 binds the KFERQ sequence of 
substrate proteins and carries them to the lysosomal membrane, where lamp2A, after 
interaction with cytosolic hsc70, multimerizes and forms a translocation complex with 
lysosomal hsc70, thus mediating the transport of the substrate protein into the lysosomal 
lumen. Several proteins with neuropathologic relevance, such as alpha-synuclein, amyloid 
precursor protein ǃ and huntingtin, contain a KFERQ motif.   
The binding of the substrate protein to lamp2A represents the limiting step of chaperone 
mediated autophagy. Oxidative stress, accumulation of substrates and the lack of nutrients 
and growth factors are all conditions determining a compensatory and cytoprotective 
activation of chaperone mediated autophagy through an increase of lamp2A levels on 
lysosomal membrane.  
The hypothesis that a dysfunction of chaperone mediated autophagy might be involved in 
the pathogenesis of Parkinson’s disease was proposed when this process was 
demonstrated to be the main degradative pathway for alpha-synuclein; indeed, this 
protein accumulates when chaperone-mediated autophagy is suppressed by down-
regulation of lamp2A expression. Therefore, the efficiency of this clearance pathway 
appears to be crucial in regulating the intraneuronal levels of alpha-synuclein. The 
evidence of a strong correlation between the functional state of chaperone mediated 
autophagy and the deleterious action of alpha-synuclein has been reinforced by 
demonstration that both pathogenetic mutations and overexpression of ǂ-synuclein 
inhibit this process (Cuervo et al 2004, Xilouri et al 2009). Experiments performed on 
animal models over-expressing alpha-synuclein have revealed that down-regulation of 
chaperone mediated autophagy is responsible for part of the alpha-synuclein toxicity in 
dopaminergic neurons. A reduced turnover of proteins directly involved in the neuronal 
survival and in the apoptotic machinery may mediate the deleterious effect of alpha-
synuclein-mediated inhibition of this clearance pathway.  
Therefore, it is conceivable to assume that other substrates of chaperone mediated 
autophagy contribute to neuronal death through their accumulation. For example, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Tatton 2000) and myocyte enhancer 
factor 2D (MEF2D) (Yang et al 2009) are substrates of this degradative pathway and, at the 
same time, are specifically involved in the molecular physiopathology of Parkinson’s 
disease; these factors could represent key mediators of the neuronal death when chaperone 
mediated autophagy is impaired.  
Besides mutations and multiplications of alpha-synuclein gene, other mutations linked to 
hereditary Parkinson’s disease are responsible for the impairment of chaperone mediated 
autophagy. Pathogenetic mutation I93M of PARK5 gene has been demonstrated to 
determine the inhibition of chaperone mediated autophagy and the accumulation of alpha-
synuclein (Kabuta et al 2008).  
The finding of low levels of lamp2A and total hsc70 in post-mortem substantia nigra of 
patients with sporadic disease indicates that a reduced activity of chaperone mediated 
autophagy is likely to be a pathogenetic mechanism even in idiopathic Parkinson’s disease 
(Alvarez-Erviti 2010).  
In conclusion, the failure of chaperone mediated autophagy seems to be a pathogenetic 
mechanism favoring the death of dopaminergic neurons and, as a consequence, contributing 
to the development and progression of Parkinson’s disease.  
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4.2.2 Macroautophagy failure 
Macroautophagy starts with sequestration of a region of cytoplasm containing proteins and 
organelles designed for degradation within a double-membrane vacuole called 
autophagosome. Once formed, the autophagic vacuole undergoes a process of maturation, 
which is essential for the subsequent fusion with lysosome and the degradation of 
substrates. The proper function of macroautophagy allows the removal of misfolded 
proteins and aberrant organelles, which are unsuitable for degradation through other 
pathways.  
Macroautophagy is regulated by the mammalian target of rapamycin (mTOR), a 
serine/threonine kinase on which two main signal transduction pathways converge: 
• The AKT pathway, modulated by neurotrophic growth factors.  
• The AMPK pathway, modulated by intracellular levels of aminoacids and ATP.  
Macroautophagy is suppressed by mTOR in presence of high levels of nutrients or when 
growth factors stimulate the cell.  
Several exogenous molecules are known to activate macroautophagy independently of 
mTOR activity. These include drugs actually used in the treatment of neurologic and non 
neurologic diseases, such as calcium antagonists, lithium and valproate.  
Macroautophagy proceeds through various steps, each requiring the presence of specific 
autophagy related genes (Atg). Four main phases can be distinguished:  
1. Nucleation of the autophagosome.  
2. Sequestration of a region of cytoplasm containing substrates to be degraded.  
3. Maturation of the autophagosome. 
4. Fusion with lysosome and degradation of substrates. 
Therefore, regulation and biological function of macroautophagy appear to be characterized 
by a remarkable complexity. Since different variants of this process exist, each one 
characterized by specific activators, regulatory pathways and biological effects.  
Although macroautophagy, chaperone mediated autophagy and ubiquitin-proteasome 
system are responsible for the degradation of different preferential substrates, a functional 
correlation among them have been demonstrated. In particular, macroautophagy is able to 
modulate its own activity depending on the efficiency of the other two pathways. Both 
proteasome and chaperone mediated autophagy inhibition determine a cytoprotective 
activation of macroautophagy. 
Macroautophagy has been implied in the pathogenesis of several neurodegenerative 
diseases, such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and 
frontotemporal dementia, as well as acute injuries. A role of macroautophagy in the 
development of these pathologies was proposed when intraneuronal accumulation of 
autophagic vacuoles was detected in postmortem brains of diseased patients; increasing 
experimental data indicate that this feature is likely to mirror a dysfunction in maturation 
and lysosomal clearance of autophagosomes.  
Macroautophagy seems to play a relevant  role in the clearance of alpha-synuclein. Both 
pathogenetic mutations and over-expression of alpha-synuclein determine an induction of 
macroautophagy, which is dependent on the inhibition of chaperone mediated autophagy 
(Xilouri et al 2009).  
Anyway, the impairment of alpha synuclein degradation seems not to have a major role in 
mediating the deleterious effect of macroautophagy impairment: the accumulation of other 
substrates might be more decisive. In this regard, it is important to remind that 
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macroautophagy represents the only mechanism able to mediate the clearance of damaged 
mitochondria through a process named mitophagy. The intraneuronal accumulation of 
aberrant mitochondria determines neurotoxic effects linked to the generation of reactive 
oxygen species and the release of pro-apoptotic mediators. Increasing evidence from 
transgenic models of disease suggests that a defect in the mitophagy pathway might exert 
an key pathogenetic role in Parkinson’s disease. In fact, genes responsible for hereditary 
disease are essential components of mitophagy machinery: PINK1 and parkin, two genes 
linked to recessive forms of Parkinson’s disease, encode proteins that work synergistically to 
ensure the sequestration of aberrant mitochondria within the autophagic vacuole Narendra 
et al 2010).  
Even DJ1, a gene linked to autosomal recessive Parkinson’s disease, encodes for a protein 
that activates macroautophagy and favors mitochondrial turnover (Krebiehl et al 2010).  
Loss of function of PINK1, parkin or DJ1 causes hereditary Parkinson’s disease and the 
death of dopaminergic neurons in cell and animal models: the decreased efficiency of 
macroautophagy and mitophagy might be responsible for part of this neurotoxic effect.  
Based on these assumptions, the efficacy of mitochondria turnover should be evaluated as a 
putative defective step linked to macroautophagy dysfunction even in idiopathic 
Parkinson’s disease. 
4.2.3 Loss of lysosomal function 
The hypothesis that macroautophagy might be impaired in Parkinson’s disease only 
apparently contrasts with the accumulation of autophagosomes and the increase of LC3II 
levels that have been demonstrated in postmortem substantia nigra of diseased patients. As 
previously reported, recent data suggest that a defect in maturation of autophagosome and 
in its fusion with lysosome could be the major responsible for the accumulation of 
autophagic vacuoles. Indeed, a depletion of the intraneuronal lysosomal pool and decreased 
levels of lysosome associated proteins, such as LAMP1, cathepsin D and heat shock protein 
73, have been detected in nigral neurons of patients with sporadic Parkinson’s disease. 
Furthermore, lysosomal depletion has been found in dopaminergic neurons of a MPTP 
mouse model (Dehay et al 2010); in this study the loss of lysosomes has been identified as an 
early alteration preceding the accumulation of autophagosomes and the neuronal 
degeneration. Oxidative injury has been found to favor lipid peroxidation of lysosomal 
membrane and, at last, to reduce the pool of lysosomes. Therefore, a strong and synergistic 
correlation seems to exist between oxidative stress and the dysfunction of autophagic-
lysosomal pathway.  
An additional proof of the protective role of lysosomal function in dopaminergic neurons 
has derived from the finding that mutations of genes encoding lysosomal proteins can 
modify the risk of developing Parkinson’s disease. ATP13A2 (PARK9) is a lysosomal 
transmembrane cation transporting ATPase that is necessary to maintain acidity in the 
lysosomal lumen; low pH is indispensable for the function of lysosomal hydrolases and, as a 
consequence, for degradation of autophagy substrates. Homozygous mutations of ATP13A2 
gene causes Kufor-Rakeb syndrome, characterized by early-onset parkinsonism with 
pyramidal degeneration and dementia. In vitro experiments have demonstrated that loss of 
ATP13A2 impairs lysosomal degradation of alpha-synuclein and cause intraneuronal 
accumulation of this protein (Gitler et al 2009).  
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Glucocerebrosidase (GBA) is a lysosomal enzyme that catalyzes the hydrolysis of the lipid 
glucosylceramide into glucose and ceramide. Homozygous mutations of GBA gene are 
responsible for Gaucher syndrome, a multisystem lysosomal storage disease characterized 
by neurodegenerative manifestations. Recently, carriers of GBA pathogenetic mutations 
have been identified at higher risk of sporadic Parkinson’s disease (Sidransky et al 2009). 
This confirms the great importance of lysosomal function for the survival of dopaminergic 
neurons.  
5. Neuropathologic outcome of molecular physiopathology: More than nigral 
degeneration 
In the previous paragraphs we have reported evidences regarding the occurrence of specific 
deleterious processes in degeneration of dopaminergic neurons; furthermore, we have 
highlighted the functional correlations that have been demonstrated among these processes. 
A wide body of data confirms that each of these mechanisms can be responsible for 
degeneration of dopaminergic neurons and involutional modifications of the substantia 
nigra. These modifications are responsible for the motor symptoms that represent the major 
criteria for diagnosis of Parkinson’s disease. The reasons of the selective damage of nigral 
neurons is not currently known; particular biological conditions might favor the onset of 
pathogenetic mechanisms in these neurons or could be responsible for an extreme 
vulnerability to systemic biochemical alterations.  
However, the selectiveness of nigral involvement in Parkinson’s disease is not absolute. In fact, 
the cardinal symptoms of Parkinson’s disease are often preceded by a series of early 
manifestations, such as depression, sleep disturbances, eye movement disorders, hyposmia, 
constipation and loss of cardiac and vasomotor reflexes, which can start several years before 
the motor disturbances. The neuropathologic substrate of these aspecific manifestations does 
not seem to be ascribable to the degeneration of substantia nigra, rather they would derive 
from the involvement of other monoaminergic neurons in central and peripheral nervous 
system. Postmortem studies in patients with Parkinson’s disease have provided evidence of a 
typical temporal pattern of pathology progression from peripheral neurons, spinal cord and 
brainstem to basal ganglia and cortical regions. These studies have revealed the precocious 
degeneration of autonomic ganglia of mesenteric plexus, dorsal motor nucleus of vagus, rafe 
nuclei, locus ceruleus and ventral tegmental area; the involvement of these centers is consistent 
with the clinical symptoms preceding parkinsonian signs. Based on these premises, the 
degeneration of substantia nigra appears as a late manifestation of the neuropathologic 
process; moreover, the onset of the characteristic motor manifestations is usually insidious and 
can be appreciated only when about 50% to 60% of dopaminergic neurons have been lost. 
These remarks indicate that the diagnosis of Parkinson’s disease is always made when the 
underlying neuropathologic process has already reached an advanced phase; this limits the 
benefits that can be expected from putative neuroprotective therapies.  Hence, it would be 
desirable to be endowed of diagnostic tools useful to make diagnosis of Parkinson’s disease 
during early or even pre-clinical stages. This assumption has promoted the pre-clinical and 
clinical research aimed at identifying biomarkers of disease.  
5.1 Peripheral biomarkers 
Different rationales justify the use of biomarkers for Parkinson’s disease: 
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• To study disease mechanisms. 
• To identify individuals with an increased risk of disease. 
• To diagnose patients before or at the threshold of motor symptoms. 
• To monitor disease progression throughout its course. 
• To establish drug mechanisms, assess drug dosing and secondary outcomes in clinical 
studies. 
Neuroimaging biomarkers include detection of dopamine transporter (DAT) levels in basal 
ganglia with radiolabeled tracers; 123I-FP-CIT SPECT, commonly known as DATscan, is 
actually used in clinical practice to assist in the differential diagnosis of movement 
disorders. Anyway, DAT depletion follows the death of nigral neurons; furthermore, the 
exposure to radiations and the high costs limit the use of this test in screening and follow 
up.  
Peripheral biochemical markers would offer the advantage of being easily accessible for 
repeated measurements, feature that makes them particularly useful not only for diagnosis 
but even for monitoring the course of the disease. Various peripheral cell types share with 
neurons the molecular machinery for several biochemical processes; this provides the 
chance of testing peripheral ex-vivo models to seek for disease-specific biochemical 
alterations. The ideal biomarker should reflect a pathogenetic mechanism operative at 
central level (core biomarker) and playing a major role in the patophysiology of Parkinson’s 
disease, such as alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress 
and impairment of the clearance machinery. Therefore, it is essential to identify peripheral 
models reproducing the molecular alterations detected in the affected neurons. Up to now, a 
wide range of putative peripheral models of disease have been proposed: platelets, 
peripheral blood mononuclear cells and fibroblasts represent ex vivo tissues which are 
actually under investigation with the aim of disclosing differences in biochemical 
parameters between patients with Parkinson’s disease and controls; even plasma is 
currently studied with the same purpose. The accessibility of peripheral tissues represent 
the clearest advantage of their use, significantly compensating the fact that they are not the 
main target of the disease.  
Cerebrospinal fluid (CSF) cannot be considered a peripheral sample, because it is not easily 
accessible; anyway, CSF represents a more direct window on central nervous system than 
blood, so that it can be analysed in pilot studies to determine biochemical alterations which 
could be more extensively assessed in peripheral models.  
The development of therapies demonstrating a pre-clinical neuroprotective effect has 
raised the need of peripheral biomarkers more and more pressing. In fact, new drugs 
tested to delay the progression of Parkinson’s disease are targeted to specific biochemical 
alterations occurring in the central nervous system; in this context, a great help would 
derive from the availability of reliable biochemical parameters linked to the targeted 
pathway, useful to monitor therapies in clinical studies. Biomarkers expected to predict 
the effect of a therapeutic intervention and assessed as substitutes for a clinically relevant 
endpoint are named surrogate markers; their use would allow to overcome some 
difficulties that often occur in clinical trials of neuroprotective therapies: a biomarker 
could give short-term information on drug biochemical efficacy, whereas clinical outcome 
can be evaluated only after years of treatment; a biomarker would not be influenced by a 
symptomatic effect that could complicate the demonstration of the neuroprotective effect 
of the drug.   
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Actually, among the putative peripheral biochemical markers which have been investigated, 
no one has a reliability which could justify its use in clinical practice.  
Alpha-synuclein levels in peripheral blood cells from patients with Parkinson’s disease do 
not seem to differ from controls (Brighina et al 2010), even if an increased expression of the 
alpha-synuclein gene has been detected in fibroblasts from patients (Hoepken et al 2008). 
Data on total plasma level of the protein in patients compared to controls are contrasting but  
new alpha-synuclein assays able to detect oligomeric protein have demonstrated changes in 
plasma and cerebrospinal fluid from diseased patients. Recently, the concentration of alpha-
synuclein oligomers and the ratio of oligomers on total alpha-synuclein have been  found 
significantly increased in cerebrospinal fluid from diseased patients compared to controls 
(Tokuda et al 2010). The oligomeric soluble fraction of alpha-synuclein has been reported to 
be increased in plasma samples obtained from patients.  
A reduction of glutamate uptake has been observed in platelets from patients and the 
decrease has showed a positive correlation with clinical severity of the disease (Ferrarese et 
al. 1999, 2001). This finding indicates that a systemic defect in glutamate transport occurs in 
patients with Parkinson’s disease.  
Some studies have reported a decrease in proteasome function in lymphocytes from 
diseased patients (Blandini et al 2006), but this finding has not been confirmed by 
subsequent experiments (Brighina et al 2010).  
Oxidative stress is induced in lymphocytes from patients with Parkinson’s disease and 
inversely correlates with L-dopa daily doses (Prigione et al 2006, 2009). Increased 
nitrotyrosine modifications of alpha-synuclein have been found in peripheral blood 
mononuclear cells obtained from individuals with idiopathic Parkinson’s disease compared 
to controls; moreover, the amount of nitrotyrosine-modified alpha-synuclein has been 
demonstrated to positively correlate with intracellular levels of reactive oxygen species; in 
the same ex vivo model a significant increase in LC3II level have been demonstrated in 
diseased patients (Prigione et al 2010). Therefore, in patients with sporadic Parkinson’s 
disease, a systemic dysregulation of autophagy and oxidative stress seem to exist and 
correlate with alpha-synuclein post-translational modifications. This confirms the chance of 
identifying peripheral biomarkers able to mirror the activation of pathogenetic processes in 
the central nervous system: biochemical parameters of autophagy and oxidative stress, 
together with qualitative and quantitative alterations of alpha-synuclein, could be useful for 
diagnostic or prognostic purposes and to monitor the biochemical effects of putative 
neuroprotective therapies. Moreover, the physiopathologic correlation among these 
mechanisms could offer the possibility of a combined use of these parameters to increase the 
accuracy of single biomarkers. In particular, the specificity of autophagy dysregulation in 
peripheral models, not confirmed in other neurodegenerative diseases, qualifies autophagy 
machinery as a new and promising target of research in the field of peripheral biochemical 
markers of disease.   
It is conceivable that neuroprotective drugs would have more chance of success if they are 
administered during early stages of disease, when the molecular pathogenetic processes 
occurring in dopaminergic neurons could be more easily blocked; therefore, the availability 
of tools useful to make early diagnosis would increase the potential neuroprotective effects 
of old and new putative therapies. Therefore, development of disease biomarkers is strongly 
related to the identification of drugs able to delay the progression of Parkinson’s disease or 
even to prevent its onset if diagnosis is made in preclinical stages. 
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5.2 Therapeutic perspectives 
Several pharmacological approaches have been tested in order to prevent dopaminergic 
neurodegeneration. It is obvious that the most promising targets of neuroprotective strategy 
for Parkinson’s disease are represented by the molecular pathogenetic mechanisms known 
to contribute to nigral degeneration.  
An ideal therapeutic approach would consist in preventing alpha-synuclein misfolding, 
accumulation and aggregation in dopaminergic neurons. Means to achieve this aim include 
the suppression of alpha-synuclein expression through siRNA technology, the development 
of agents able to rescue the formation of toxic oligomeric intermediates, the induction of the 
neuronal pathways involved in alpha-synuclein degradation. The first two strategies will be 
tested in the near future, whereas the stimulation of clearance pathways is actually subjected 
to intense research. 
Different drugs have been successfully used to induce macroautophagy in cell and animal 
models of disease. Anyway, the use of these interventions to prevent neurodegeneration is 
limited by the lack of specificity; indeed, most of the tested drugs affect major intracellular 
pathways, thus explaining a series of undesired side effects. Molecules that activate the 
transcriptional factor EB, responsible for the induction of lysosomal biogenesis, have proved 
a neuroprotective effect in cell and animal models of disease (Dehay et al 2010). In 
particular, rapamycin and trehalose, two largely used macroautophagy inducers, have 
demonstrated to rescue neurons from the toxicity of various stimuli related to Parkinson’s 
disease. The effectiveness of these two molecules seems to derive from their property to 
modulate the two most critical steps of macroautophagy: they induce the formation of 
autophagosomes through an mTOR-dependent (rapamycin) or mTOR-independent 
(trehalose) mechanism; furthermore, they activate the transcription factor EB, determining 
an increase of lysosomal biogenesis, so that the increased sequestration of cargoes within the 
autophagosomes is balanced by an increase of lysosomal function, thus preventing the 
intracellular accumulation of autophagic vacuoles. This might represent a reasonable model 
to develop therapeutic tools aimed at activating macroautophagy. Ongoing screenings to 
identify novel specific macroautophagy enhancers should provide, in coming years, novel 
agents useful to modulate macroautophagy for  therapeutic purposes.  
No effective strategies are available to activate the ubiquitin-proteasome system; 
pharmacologic research has focused on increasing the proteolytic activity of proteasome 
subunits, but ubiquitin targeting and substrate deubiquitinization are all possible target of 
future therapies which could be tested.  
The importance of chaperone mediated autophagy in the degradation of alpha-synuclein 
makes it a priority to identify compounds able to stimulate this pathway. In this regard, the 
pharmacologic increase of lamp2a levels on  lysosomal membrane appears as the most 
reasonable approach. Genetic overexpression of lamp2A has been demonstrated to 
upregulate chaperone mediated autophagy in animal models but pharmacologic tools able 
to obtain the same effect are currently not available; cholesterol-depleting agents has shown 
to enhance the activity of chaperone mediated autophagy through disruption of lysosome 
membrane lipid microdomains, where inactive lamp2A is stored. 
As previously reported, sirtuins have been identified as mediators of modifications induced 
by starvation in dopaminergic neurons of animals; in particular, SIRT2 seems to enhance the 
toxic effect of alpha-synuclein, whereas SIRT1 has demonstrated to exert a protective role in 
dopaminergic neurons. These discoveries have led to the search for potential therapeutic 
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targets among SIRTs. Promising pharmacologic approaches include stimulation of SIRT1, 
which imitates the protective effects produced by caloric restriction in animals, and 
inhibition of SIRT2. 
Stimulation of mitochondrial function might represent another target of putative 
neuroprotective drugs for Parkinson’s disease. Resveratrol is a molecule that has been 
demonstrated to induce genes involved in mitochondrial biogenesis and aerobic 
metabolism; this drug rescues dopaminergic neurons in MPTP mouse models. 
Several studies have evaluated the putative neuroprotective role of treatments aimed at 
reducing oxidative stress. An evidence of the potential benefit of antioxidant treatment in 
Parkinson’s disease has been the finding that induction of glutathione peroxidase expression 
determines a protective effect against 6-hydroxydopa toxicity in dopaminergic neurons of 
mice. Similarly, overexpression of glutathione peroxidase, as well as Cu, Zn-superoxide 
dismutase, protects murine brain against paraquat-induced neurodegeneration.  
Several foods and natural molecules are supposed to exert a neuroprotective effect thanks 
to their antioxidant properties. Soy component genistein increases cellular reduced 
glutathione. Green tea contains polyphenols and flavonoids that prevent lipid 
peroxidation; another substance contained in green tea, epigallocatechin 3-gallate, has 
been demonstrated to stimulate nigrostriatal transmission and prevent dopaminergic 
neuronal loss through suppression of nitric oxide levels in a MPTP mouse model; this 
finding has qualified nitrosative stress as a putative target of neuroprotective therapies: 7-
nitroindazole, a synthetic inhibitor of nitric oxide synthase, has been shown to prevent 
neurodegeneration in MPTP animal models. Administration of supplements of coenzyme 
Q10, an endogenous antioxidant that acts as an electron transporter for mitochondrial 
complexes I and II, has been found to increase the activity of mitochondrial complex I in 
patients with Parkinson’s disease and to prevent dopaminergic neuronal degeneration in 
a mouse model of disease.  
Different plant extracts have antioxidant properties and produce positive effects on 
experimental models of Parkinson’s disease. Withania somnifera belongs to the solanaceae 
family, extensively used in Indian Ayurvedic medicine. This plant contains various 
alkaloids which might mediate its putative therapeutic effects. Recent studies have shown 
that administration of extract from w. somnifera increases the levels of antioxidant 
molecules in the midbrain and corpus striatum of mouse models of Parkinson’s disease; 
furthermore, this treatment has produced an improvement in dopaminergic transmission 
and motor function in the same models (Rajasankar et al 2009).  
Use of non-steroidal anti-inflammatory medications seems to reduce the risk of Parkinson’s 
disease, probably as a consequence of a decreased generation of free radicals and nitric 
oxide in dopaminergic neurons.  
Antioxidant therapies have demonstrated to be effective at preventing alpha-synuclein 
aggregation and neuronal death in many cellular and animal models of PD but clinical 
studies have failed to demonstrate any significant effect on disease progression in patients. 
Propalgylamines (selegiline and rasagiline) are drugs actually used in clinical practice for 
the treatment of Parkinson’s disease. These molecules seem to positively modify the natural 
history of the disease thanks to their antioxidant effect, partially related to the inhibition of 
MAO-B-mediated dopamine catabolism (Magyar et al 2010). The neuroprotective effect of 
propalgylamines  has been demonstrated in various models of disease but it has not been 
definitely proved in patients. In fact, MAO-B inhibition is also responsible for an 
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improvement in motor symptoms, based on the increase of dopaminergic nigrostriatal 
transmission, so that it is difficult to distinguish symptomatic from neuroprotective effect. 
this confirms the need of a peripheral, pathology-related biomarker, useful as a surrogate 
endpoint in clinical trials of neuroprotective drugs. Anyway, molecular mechanisms 
different from MAO-B inhibition are supposed to contribute to the putative neuroprotective 
effect of selegiline and rasagiline: propargylamines have demonstrated to prevent 
mitochondrial permeabilization, cytochrome c release, caspase activation and nuclear 
translocation of glyceraldehyde 3-phosphate dehydrogenase; moreover, rasagiline induces 
the expression of anti-apoptotic proteins, such as Bcl-2 and glial cell-line derived 
neurotrophic factor (GDNF).  
Drugs interfering with excitotoxic insult, such as the NMDA antagonist amantadine, 
produce little improvement in motor parkinsonian symptoms and significantly reduce 
motor side effects of L-dopa treatment. Although NMDA antagonists have been found to 
prevent nigral degeneration in animal models of Parkinson’s disease (Blandini et al 2001), no 
neuroprotective effect has been demonstrated in patients.  
Dopaminergic drugs, such as L-dopa and dopamine agonists, as well as deep brain 
stimulation, might determine neuroprotective effects based on the hypothesis that an 
increase of dopaminergic transmission should inhibit the glutammatergic projection from 
subthalamus to the substantia nigra.  
6. Conclusions 
Molecular physiopathology of Parkinson’s disease represents an intricate cascade of events 
that researchers have only begun to clarify (Fig. 1). The association that has been established 
between nigral degeneration and alpha-synuclein modifications has found its confirmation 
in a growing body of experimental evidences. Anyway, the primitive conditions that  are 
responsible for the toxic gain of function of this protein, as well as the molecular properties 
of aberrant alpha-synuclein that are responsible for its deleterious effect on neuronal 
homeostasis, are mostly unknown and must be further explored. The precise assessment of 
the sequence of events leading to alpha-synuclein oligomerization and to neuronal death is 
undoubtedly an essential step in the research of neuroprotective tools; an ideal goal would 
consist in the identification of critical nodes in the molecular physiopathology of Parkinson’s 
disease, which may provide novel promising targets of therapies aimed at blocking the 
degenerative process.  
Mitochondrial impairment and oxidative stress seem to be early features responsible for 
alpha-synuclein modifications favoring protein misfolding and aggregation, but the 
same mechanisms can be induced by the same alpha-synuclein oligomers that they 
contribute to produce, so that a linear sequence of events cannot be established. 
Glutammatergic overstimulation of nigral neurons seems to exert a major role in the 
genesis of motor symptoms, whereas excitotoxicity probably plays a secondary role that 
only accelerates the death of neurons when these are exposed to energetic defects, 
oxidative stress and other toxic features. Therefore, it is possible to argue that a 
significant neuroprotective effect is unlikely to be obtained through pharmacologic 
interference with only one of these mechanisms, as it is confirmed by the failure of 
multiple selective strategies aimed at stimulating mitochondrial function or at 
contrasting oxidative stress or excitotoxicity.  
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 : genetic factors;     : environmental factors;     : therapeutic strategies.       
Fig. 1. Scheme illustrating genetic and enviromental factors involved in alpha-synuclein (ǂ-
SYN ) toxicity and possible therapeutic targets. CMA: chaperone mediated autophagy 
Therapeutic tools able to remove alpha-synuclein oligomers or to favor the protein refolding 
are not currently available. Anyway, several data support a critical role for the efficiency of 
the intracellular clearance machinery in the maintenance of neuronal integrity; in fact, 
strong links have been established between abnormal functioning of surveillance pathways 
and the pathogenesis of Parkinson’s disease. Ubiquitin-proteasome system represents the 
first degradative pathway which has been investigated, however its importance has been 
downsized by the finding of its secondary role in the degradation of alpha-synuclein, which 
remains the most disease-specific pathogenetic factor. In this context, the scientific attention 
has switched to autophagy. Alpha-synuclein, UCH-L1, ATP13A2, DJ1 and PINK1 have all 
been demonstrated to regulate the clearance of proteins and mitochondria through 
autophagic-lysosomal pathway. Furthermore, the loss of a single allele of the 
glucocerebrosidase gene seems to be sufficient to increase the risk of developing the disease. 
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Pathogenetic mutations of genes responsible for recessive forms of Parkinson’s disease, such 
as DJ1, PINK1 and ATP13A2, inhibit autophagy or lysosomal function through a loss of 
function of the encoded protein, whereas mutations of genes linked to dominant forms of 
the disease, such as alpha-synuclein and UCH-L1, impair autophagy through a gain of an 
aberrant function. Therefore, a correspondence exists between the type of transmission of 
the hereditary disease and the mechanism through which muted proteins impair 
autophagy. Furthermore, several studies performed on postmortem brains and on cell and 
animal models of disease have confirmed that a failure of the autophagic-lysosomal 
pathway is likely to be a key feature of the disease physiopathology. This defect can trigger 
all the well-known pathogenetic mechanisms involved in Parkinson’s disease, which in turn 
can worsen the efficiency of autophagy. Together, these evidences sustain the hypothesis of 
a central involvement of autophagic and lysosomal dysfunction in the pathogenesis of 
Parkinson’s disease.  
The fact that the intraneuronal surveillance machinery has been demonstrated to contrast 
the onset of most pathogenetic mechanisms of Parkinson’s disease makes the recovery and 
the improvement of this cell quality-control a priority in the development of new 
therapeutic strategies. Pharmacologic approaches aimed at promoting the removal of 
aberrant proteins and organelles could reveal as the most rationale and global solution 
applicable to delay the progression of Parkinson’s disease and other neurodegenerative 
disease related to protein misfolding.  
In conclusion, restoring the normal function of autophagic-lysosomal pathway, together 
with reducing oxidative stress and favouring alpha-synuclein refolding, represent 
promising strategies of neuroprotective therapies. Anyway, all these approaches still face 
some limitations that need to be overcome; the identification of early diagnostic biomarkers 
remains an absolute priority that could allow to overcome part of these limitations.  
An accurate knowledge of the wide range of mechanisms involved in the physiopathology 
of Parkinson’s disease and, firstly, the definition of the complex interactions connecting 
these mechanisms represent basic requirements to develop diagnostic instruments and 
therapeutic tools able to modify the natural course of this disease.  
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